Accelerates Enrollment Timeline for the Cardiac Catheter IDE Conference Call to Be Held Thursday, May 7th to Discuss Business Updates and Financial Results...
Multicenter results show sustained high durability and procedural efficiency, redefining positive expectations for catheter ablation in patients with atrial fibrillation
nPulse™ Technology highlighted in late-breaking feasibility study and live case transmission
Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter System
Appoints Liane Teplitsky as Chief Operating Officer Expands Dr. David Kenigsberg’s Chief Medical Officer Role
U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study
Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced plans to present at the upcoming 25 ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and...
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first...
Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment.